お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
966836

腫瘍浸潤リンパ球 (TIL) 免疫療法の世界市場 - 機会:臨床試験の考察

Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025

出版日: | 発行: KuicK Research | ページ情報: 英文 150 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

腫瘍浸潤リンパ球 (TIL) 免疫療法の世界市場 - 機会:臨床試験の考察
出版日: 2020年10月22日
発行: KuicK Research
ページ情報: 英文 150 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん治療における免疫療法サーベイランスの登場により、がん治療のために免疫細胞を操作することへのフォーカスが、研究者による重要な戦略になりました。現在、免疫療法市場は、がん患者からの腫瘍細胞の完全寛解を引き起こすための腫瘍浸潤リンパ球 (TIL) の開発に起因しています。

当レポートでは、世界の腫瘍浸潤リンパ球 (TIL) 免疫療法市場について調査分析し、パイプライン、治験情勢、市場情勢、コスト予想、市場機会などについて、体系的な情報を提供しています。

目次

第1章 腫瘍浸潤リンパ球 (TIL) 療法のイントロダクション

  • 概要概要
  • 歴史的発展

第2章 がん管理における腫瘍浸潤リンパ球 (TIL) 療法の役割

第3章 黒色腫における腫瘍浸潤リンパ球 (TIL)

  • 黒色腫におけるTIL療法の現在の適応
  • 後期黒色腫における単剤療法以上のTIL
  • 最近の研究と進歩

第4章 大腸がんにおける腫瘍浸潤リンパ球 (TIL)

  • 大腸がんにおけるTILの役割
  • 進行中の開発

第5章 消化器がんにおける腫瘍浸潤リンパ球 (TIL)

  • 胃がんのTIL
  • 膵臓がん
  • 肝細胞がん(肝がん)

第6章 肺がんにおける腫瘍浸潤リンパ球 (TIL)

  • 肺がんの予後パラメーターとしてのTIL
  • NSCLCを標的とするTIL:現在のシナリオ

第7章 婦人科がんにおける腫瘍浸潤リンパ球 (TIL)

  • 卵巣がんにおけるTILの影響
  • 子宮/子宮内膜がん
  • 子宮頸がん

第8章 泌尿生殖器がんに対する腫瘍浸潤リンパ球 (TIL) 療法

  • 膀胱/尿路がん
  • 腎細胞がん(RCC)
  • 前立腺がん

第9章 頭頸部がんにおける腫瘍浸潤リンパ球 (TIL)

  • 頭頸部がんにおけるTILの影響
  • 進行中の研究と進歩

第10章 脳腫瘍における腫瘍浸潤リンパ球 (TIL)

  • 神経膠腫・髄膜腫におけるTILの役割
  • 脳腫瘍を標的とする最近の進歩

第11章 乳がんにおける腫瘍浸潤リンパ球 (TIL)

  • 乳がん治療薬としてのTIL
  • 進行中の開発

第12章 血液がんにおける腫瘍浸潤リンパ球 (TIL)

第13章 世界の腫瘍浸潤リンパ球 (TIL) 臨床パイプライン:企業別、適応症別、フェーズ別

  • フェーズI
  • フェーズII

第14章 世界の腫瘍浸潤リンパ球 (TIL) 療法市場分析

  • 個別化治療としての腫瘍浸潤リンパ球 (TIL) 療法市場の成長フロンティア
  • 現在の市場シナリオ
  • 治療費分析

第15章 腫瘍浸潤リンパ球 (TIL) 市場の最近の研究動向と開発

第16章 腫瘍浸潤リンパ球 (TIL) 療法市場に関連する促進要因と課題

第17章 腫瘍浸潤リンパ球 (TIL) 療法市場の将来考察

第18章 競合情勢

  • Iovance Biotherapeutics
  • Optera Therapeutics
  • TILT Therapeutics
図表

List of Figures

  • Figure 1-1: Procedure of Tumor Infiltrating Lymphocytes Therapy
  • Figure 1-2: Evolution of Tumor Infiltrating Lymphocytes (TIL) Therapy
  • Figure 2-1: Role of Tumor Infiltrating Lymphocytes (TIL) in Cancer
  • Figure 2-2: Approach for Tumor Infiltrating Lymphocytes Evaluation in Solid Tumors
  • Figure 3-1: US - Lifileucel & LN-145 Orphan Drug Designation Year
  • Figure 3-2: Therapies Used in Combination with Tumor Infiltrating Lymphocytes Therapy
  • Figure 3-3: Tumor Infiltrating Lymphocytes as Adjuvant Therapy of Melanoma
  • Figure 3-4: C-144-01 Trial - Study Initiation & Expected Completion Year
  • Figure 4-1: Role of Tumor Infiltrating Lymphocytes in Colorectal Cancer
  • Figure 4-2: MDA-TIL Trial - Study Initiation & Expected Completion Year
  • Figure 5-1: Global - Number of Newly Diagnosed Cases of Leading Gastrointestinal Cancer, 2020
  • Figure 5-2: Global - Number of Deaths by Leading Gastrointestinal Cancer, 2020
  • Figure 5-3: Role of Tumor Infiltrating Lymphocytes in GI Cancers
  • Figure 5-4: Type of Infiltrated T-Cells in Lung Cancer
  • Figure 5-5: Infiltrated T-Cells Assisting the Prognosis of Liver Cancer
  • Figure 6-1: Tumor Infiltrating Lymphocytes Treatment for Lung Cancer
  • Figure 6-2: Type of Infiltrated T-Cells in Lung Cancer
  • Figure 7-1: Global - Number of Newly Diagnosed Cases of Leading Gynecological Cancer, 2020
  • Figure 7-2: Global - Number of Deaths by Leading Gynecological Cancer, 2020
  • Figure 7-3: Role of Tumor Infiltrating Lymphocytes in Various Gynecological Cancer
  • Figure 7-4: TILs Treatment for Ovarian Cancer
  • Figure 7-5: Type of Infiltrated T-Cells for Prognosis of Ovarian Cancer
  • Figure 7-6: OVSTAR TIL Trial: Study Initiation & Expected Completion Year
  • Figure 7-7: Ovarian Cancer Targeting Tumor Infiltrating Lymphocytes Therapies in Clinical Trials
  • Figure 8-1: Global - Number of Newly Diagnosed Cases of Leading Genitourinary Cancer, 2020
  • Figure 8-2: Global - Number of Deaths by Leading Genitourinary Cancer, 2020
  • Figure 8-3: Infiltrated T-cells in Urothelial Cancer
  • Figure 8-4: Infiltrated T-Cells in Renal Cell Carcinoma
  • Figure 8-5: Tumor Infiltrating Lymphocytes Therapy Procedure for Prostate Cancer
  • Figure 8-6: T-cells Infiltrated in Prostate Cancer
  • Figure 9-1: Global - Newly Diagnosed Cases & Deaths related to Head & Neck Cancer, 2020
  • Figure 9-2: Tumor Infiltrating Lymphocytes Therapy Procedure for Targeting Head & Neck Cancer
  • Figure 9-3: C-145-03 Trial - Study Initiation & Expected Completion Year
  • Figure 10-1: Global - Newly Diagnosed Cases & Deaths related to Brain Cancer, 2020
  • Figure 10-2: Role of Tumor Infiltrating Lymphocytes Therapy in Brain Tumor
  • Figure 10-3: Infiltrated T-Cells in Brain Tumor
  • Figure 11-1: Global - Newly Diagnosed Cases & Deaths related to Breast Cancer (Million), 2020
  • Figure 11-2: Tumor Infiltrating Lymphocytes Therapy Procedure for Breast Cancer
  • Figure 11-3: Evaluation of TILs for Breast Cancer
  • Figure 11-4: LN-145 Breast Cancer Trial - Study Initiation & Expected Completion Year
  • Figure 12-1: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 12-2: Global - Newly Diagnosed Cases by Leading Types of Blood Cancer, 2020
  • Figure 12-3: Tumor Infiltrating Lymphocytes Therapy Procedure in Leukemia
  • Figure 12-4: Type of Beneficial Infiltrating Cells in Leukemia
  • Figure 12-5: Type of Beneficial Infiltrating Cells in Lymphoma
  • Figure 13-1: Tumor Infiltrating Lymphocytes Clinical Pipeline by Phase (%), 2020
  • Figure 14-1: US - Minimum & Maximum Cost of Tumor Infiltrating Lymphocytes Therapy Treatment, October'2020
  • Figure 14-2: Proleukin - Cost of Single Powder for Injection, Single Day & Full Treatment (US$), October'2020
  • Figure 14-3: Cyclophosphamide - Cost of various Supplies of Powder for Injection (US$), October'2020
  • Figure 14-4: Cyclophosphamide - Price of 2.5ml Supply & Price per ml of Intravenous Solution (US$), October'2020
  • Figure 14-5: Cyclophosphamide - Average Cost of Single Day & Full Treatment (US$), October'2020
  • Figure 14-6: Fludarabine - Average Cost of Single Day & Full Treatment (US$), October'2020
  • Figure 16-1: Driving Forces for Tumor Infiltrating Therapy Market
  • Figure 17-1: Global - Future Drivers for Tumor Infiltrating Lymphocyte Therapy Market
  • Figure 17-2: Global - Future Regional Powers for Tumor Infiltrating Lymphocyte Therapy Market
目次

"Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" Report Highlights:

  • Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies
  • Highest Phase of Development for Tumor Infiltrating Lymphocytes Immunotherapy : Phase II Trials
  • USA To Dominate Global Tumor Infiltrating Lymphocytes Immunotherapy Market Landscape
  • Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000
  • TIL Therapy Can Drive Personalized Cancer Therapy Market

With the emergence of immunotherapy surveillance in the treatment of cancer, the focus towards manipulating immune cells for cancer treatment has become an important strategy to be anticipated by the researchers. Now-a-days, the market of immunotherapy is more attributed towards developing Tumor-Infiltrating Lymphocytes for causing complete remission of the tumor cells from the cancer patients. The treatment regimen associated with the TIL therapy comprises of collection of lymphocytes that have the ability to engage themselves in the tumor cells destruction. The therapy is completely dependent on the tumor biopsy extracted from the patients rather than circulating T cells in the blood.

Despite of having numerous advantages associated with the available immunotherapies, scientists have come across with a more research emphasized therapy that is capable of demolishing minute dysfunctions in the other available immunotherapies. In view of the wide range capabilities of the therapy as per the research activity outcomes, the therapy has been able to enable a modern era of cancer therapeutics. The spurt of knowledge available for the TILs has completely changed the concept of using simple cells infiltrating from the tumors as a novel and efficient treatment regimen. In recent years also, the explosion that the market is experiencing in terms of research and drugs in the clinical pipeline is also leading towards accelerated market growth and future frontiers development.

Clinical trials regarding the therapy alone as well as in combination with the other agents are also leading to a substantial rise in the therapy acceptance. The availability of uniformity for the research anticipated as well as the progressive impeccable methodologies associated with the market are also estimated to deliver a tremendous scope for the market in the future. Also, the market is adjoined with various clinical stage biotechnology companies focusing on the development as well as commercialization of the TIL therapy for the cancer patients. The conventional as well as several guided programs developed for the market are believed to functionally categorize the therapy as one of the most prevalent and promising cancer treatment facility.

As per "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" report findings, it is estimated that the innovative research and development sector has excited the oncology researchers for driving the overall oncology pharmaceutical industry. In the past few years, the market has observed an increasing number of bio-pharmaceutical companies, leading to the rise in the competition for developing more targets that could generate more progressive outcomes at pre-clinical level and clinical level. It is estimated that the novel clinical assets in the TIL therapy will shorten the market cycles for other viable cancer therapies by rapidly following the quick launch strategy for the products under TIL therapy. It is believed that the evolving landscape of the therapy in terms of R&D activity and bio-pharmaceutical companies will fundamentally develop several dominant traits for the therapy in the next few years.

Table of Contents

1. Introduction to Tumor Infiltrating Lymphocytes (TIL) Therapy

  • 1.1 Overview
  • 1.2 Historical Development of Tumor Infiltrating Lymphocytes Therapy

2. Role of Tumor Infiltrating Lymphocytes Therapy in Cancer Management

3. Tumor Infiltrating Lymphocytes in Melanoma

  • 3.1 Current Application of TIL Therapy in Melanoma
  • 3.2 TIL Beyond Monotherapy in Late Stage Melanoma
    • 3.2.1 TIL as Combinational Therapy
    • 3.2.2 TIL as Adjuvant Therapy
  • 3.3 Recent Research & Advancements

4. Tumor Infiltrating Lymphocytes in Colorectal Cancer

  • 4.1 Role of TIL in Colorectal Cancer
  • 4.2 Ongoing Development

5. Tumor Infiltrating Lymphocytes in Gastrointestinal Cancers

  • 5.1 TIL in Gastric Cancer
  • 5.2 Pancreatic Cancer
  • 5.3 Hepatocellular Carcinoma (Liver Cancer)

6. Tumor Infiltrating Lymphocytes in Lung Cancers

  • 6.1 TIL as Prognostic Parameter for Lung Cancer
  • 6.2 TIL for Targeting NSCLC - Current Scenario

7. Tumor Infiltrating Lymphocytes in Gynecological Carcinomas

  • 7.1 Impact of TIL in Ovarian Cancer
    • 7.1.1 Therapeutic & Prognostic Potential Against Ovarian Cancer
    • 7.1.2 Ongoing Development
  • 7.2 Uterine/Endometrial Cancer
  • 7.3 Cervical Cancer

8. Tumor Infiltrating Lymphocytes Therapy for Genitourinary Cancers

  • 8.1 Bladder/Urothelial Carcinoma
    • 8.1.1 Applications of TILs in Urothelial Carcinoma
    • 8.1.2 Ongoing Development
  • 8.2 Renal Cell Carcinoma (RCC)
  • 8.3 Prostate Cancer

9. Tumor Infiltrating Lymphocytes in Head & Neck Cancer

  • 9.1 Impact of TILs in Head & Neck Cancer
  • 9.2 Ongoing Research & Advancements

10. Tumor Infiltrating Lymphocytes in Brain Tumors

  • 10.1 Role of TIL in Glioma & Meningioma
  • 10.2 Recent Advancements for Targeting Brain Cancer

11. Tumor Infiltrating Lymphocytes in Breast Cancer

  • 11.1 TIL as Breast Cancer Therapeutics
  • 11.2 Ongoing Development

12. Tumor Infiltrating Lymphocytes in Blood Cancer

13. Global Tumor Infiltrating Lymphocytes Clinical Pipeline By Company, Indication & Phase

  • 13.1 Phase-I
  • 13.2 Phase-II

14. Global Tumor Infiltrating Lymphocytes Therapy Market Analysis

  • 14.1 Growing Frontier for Tumor Infiltrating Lymphocyte Therapy Market as Personalized Treatment
  • 14.2 Current Market Scenario
  • 14.3 Therapy Cost Analysis

15. Recent Research Trends & Development for Tumor Infiltrating Lymphocytes Market

  • 15.1 Harnessing the Immune System with the help of Tumor-Infiltrating Lymphocytes
  • 15.2 Tumor-Infiltrating Lymphocytes & IL-18 Acting as Promising Novel Cancer Therapies
  • 15.3 Lovance Biotherapeutics Presentation for Tumor Infiltrating Lymphocyte Clinical Data
  • 15.4 MacroGenics Clinical Data for Presentation for MGD019 for Advanced Solid Tumor
  • 15.5 TILT Biotherapeutics Announces TILT-123 Trial for Tumor Infiltrating Lymphocyte Therapy on Patients
  • 15.6 Personalized Cell Therapy Development using Tumor-Infiltrating Lymphocytes by Neogene Therapeutics
  • 15.7 Immunosuppressive Tumor-Infiltrating T Regulatory (TITR) Cells to be the Next Target for Gilead
  • 15.8 Lovance & Genocea to Collaborate for Developing Neoantigen Targeted Tumor-Infiltrating Lymphocytes Products
  • 15.9 Orgenesis & Israel Public Hospital to Work Together for Expanding Tumor-Infiltrating Lymphocytes
  • 15.10 Lovance Biotherapeutics & Cellectis to Collaborate for Developing Tumor Infiltrating Lymphocyte Products for Cancer Patients
  • 15.11 Cellular Biomedicine & National Cancer Institute Collaboration for the Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology against Solid Tumors
  • 15.12 Lovance Biotherapeutics to Collaborate with WuXi to Advance the Tumor Infiltrating Lymphocyte Therapies TIL-01 & TIL-04
  • 15.13 Lonza & Coccon to Drive Autologous Cell Therapy Protocols for Tumor-Infiltrating Lymphocytes (TILs) & Mesenchymal Stem Cells (MSCs)
  • 15.14 Lovance Therapeutics & Lytix Biopharma Collaboration for Developing Novel Tumor-Infiltrating Lymphocytes
  • 15.15 Phase II Clinical Study for Tumor-Infiltrating Lymphocytes in Case of Metastatic Melanoma & Lung Cancer
  • 15.16 Tumor Infiltrating Lymphocyte Therapy Boosted with Interleukin-2 Introduction
  • 15.17 University of Pittsburgh Clinical Trial for Tumor Infiltrating Lymphocyte for Biliary Tract Cancer
  • 15.18 Yale University Researchers to Study Tumor-Infiltrating Lymphocytes for Triple Negative Breast Cancer
  • 15.19 Tumor Infiltrating Lymphocyte Therapy Phase Trial for Patients with Platinum Resistant Ovarian Cancer
  • 15.20 Lion Biotechnologies & PolyBioCept AB/ Karolinska University Hospital to Collaborate for Tumor-Infiltration Lymphocyte Therapy Market Expansion & Selection for Multiple Cancer Indications

16. Drivers & Challenges Associated with Tumor Infiltrating Lymphocyte Therapy Market

  • 16.1 Drivers Boosting the Overall Tumor Infiltrating Lymphocyte Therapy Market Growth
  • 16.2 Challenges Concerning the Market Growth for Tumor Infiltrating Lymphocyte Therapy

17. Future Insight for Tumor Infiltrating Lymphocyte Therapy Market

18. Competitive Landscape

  • 18.1 Iovance Biotherapeutics
  • 18.2 Optera Therapeutics
  • 18.3 TILT Therapeutics
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.